Advances and prospects in adoptive cell transfer therapy for ovarian cancer-Reference-Cited by-同舟云学术

Advances and prospects in adoptive cell transfer therapy for ovarian cancer

Published:2015-06 Issue:5 Volume:7 Page:473-476
ISSN:1750-743X
Container-title:Immunotherapy
language:en
Short-container-title:Immunotherapy

Author:

Urbanska Katarzyna¹,Powell Daniel J¹²

Affiliation:

1. Ovarian Cancer Research Center, Department of Obstetrics & Gynecology, University of Pennsylvania, 3400 Civic Center Blvd, Bldg. 421, Philadelphia, PA 19104-5156, USA

2. Perelman School of Medicine, Department of Pathology & Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA

Publisher

Future Medicine Ltd

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.futuremedicine.com/doi/pdf/10.2217/imt.15.21

Reference23 articles.

1. Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer

2. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

3. Systematic Analysis of Immune Infiltrates in High-Grade Serous Ovarian Cancer Reveals CD20, FoxP3 and TIA-1 as Positive Prognostic Factors

4. Tumor-Infiltrating Lymphocytes Expressing the Tissue Resident Memory Marker CD103 Are Associated with Increased Survival in High-Grade Serous Ovarian Cancer

5. Surveillance of the Tumor Mutanome by T Cells during Progression from Primary to Recurrent Ovarian Cancer

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cell therapies in ovarian cancer;Therapeutic Advances in Medical Oncology;2021-01

2. Immunotherapy Advances for Epithelial Ovarian Cancer;Cancers;2020-12-11

3. Preclinical and Clinical Immunotherapeutic Strategies in Epithelial Ovarian Cancer;Cancers;2020-07-02

4. Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study;Journal of Clinical Oncology;2020-06-01

5. Clinical Trials of Novel Targeted Therapies in Ovarian Cancer: Moving Beyond Poly ADP Ribose Polymerase (PARP) Inhibitors;Current Pharmaceutical Biotechnology;2019-01-23